The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population

Brad Yuan, Melvyn H. Klein, Robert S. Contiguglia, Jeffrey L. Mishell, Paul A. Seligman, Nancy L. Miller, Bruce Molitoris, Allen C. Alfrey, Joseph I. Shapiro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious. Causes of anemia in chronic renal failure are multiple, and at the present time there is no marker for aluminum-induced anemia. Deferoxamine (DFO) treatment can correct aluminum-related anemia and microcytosis, but may be associated with side effects. Because of the possible role of aluminum in red blood cells in causing the anemia associated with aluminum overload, we attempted to test red blood cell (RBC) aluminum as a marker for aluminum-associated anemia and to assess the prevalence of aluminum-associated anemia in an outpatient dialysis population. Both random plasma aluminum and RBC aluminum correlated well with the increase in plasma aluminum seen following DFO challenge. However, RBC aluminum was affected less by changes in oral aluminum intake than plasma aluminum. There were strong correlations of RBC and plasma aluminum to corpuscular volume (MCV) in our patients. Moreover, patients within the highest quartile of RBC aluminum had a lower mean MCV (82.1 ′ 1.7 vs 89.6 ′ 1.7, p <01) and hematocrit (HCT) (24.3 ′; 4 vs 28.2 ′ 1.5, p <05) than those within the lowest quartile. These data suggest that aluminum toxicity is an important cause of microcytic anemia in outpatient hemodialysis patients. Prospective long-term studies are needed to further define the usefulness of RBC aluminum in diagnosing and following hemodialysis patients with aluminum-induced anemia.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalRenal Failure
Volume11
Issue number2-3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Aluminum
Renal Dialysis
Anemia
Outpatients
Population
Erythrocytes
Deferoxamine
Dialysis

ASJC Scopus subject areas

  • Nephrology
  • Critical Care and Intensive Care Medicine

Cite this

Yuan, B., Klein, M. H., Contiguglia, R. S., Mishell, J. L., Seligman, P. A., Miller, N. L., ... Shapiro, J. I. (1989). The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. Renal Failure, 11(2-3), 91-96. https://doi.org/10.3109/08860228909066949

The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. / Yuan, Brad; Klein, Melvyn H.; Contiguglia, Robert S.; Mishell, Jeffrey L.; Seligman, Paul A.; Miller, Nancy L.; Molitoris, Bruce; Alfrey, Allen C.; Shapiro, Joseph I.

In: Renal Failure, Vol. 11, No. 2-3, 1989, p. 91-96.

Research output: Contribution to journalArticle

Yuan, B, Klein, MH, Contiguglia, RS, Mishell, JL, Seligman, PA, Miller, NL, Molitoris, B, Alfrey, AC & Shapiro, JI 1989, 'The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population', Renal Failure, vol. 11, no. 2-3, pp. 91-96. https://doi.org/10.3109/08860228909066949
Yuan B, Klein MH, Contiguglia RS, Mishell JL, Seligman PA, Miller NL et al. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. Renal Failure. 1989;11(2-3):91-96. https://doi.org/10.3109/08860228909066949
Yuan, Brad ; Klein, Melvyn H. ; Contiguglia, Robert S. ; Mishell, Jeffrey L. ; Seligman, Paul A. ; Miller, Nancy L. ; Molitoris, Bruce ; Alfrey, Allen C. ; Shapiro, Joseph I. / The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population. In: Renal Failure. 1989 ; Vol. 11, No. 2-3. pp. 91-96.
@article{5e4d53c9c1bd42999f6596a70e17e086,
title = "The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population",
abstract = "Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious. Causes of anemia in chronic renal failure are multiple, and at the present time there is no marker for aluminum-induced anemia. Deferoxamine (DFO) treatment can correct aluminum-related anemia and microcytosis, but may be associated with side effects. Because of the possible role of aluminum in red blood cells in causing the anemia associated with aluminum overload, we attempted to test red blood cell (RBC) aluminum as a marker for aluminum-associated anemia and to assess the prevalence of aluminum-associated anemia in an outpatient dialysis population. Both random plasma aluminum and RBC aluminum correlated well with the increase in plasma aluminum seen following DFO challenge. However, RBC aluminum was affected less by changes in oral aluminum intake than plasma aluminum. There were strong correlations of RBC and plasma aluminum to corpuscular volume (MCV) in our patients. Moreover, patients within the highest quartile of RBC aluminum had a lower mean MCV (82.1 ′ 1.7 vs 89.6 ′ 1.7, p <01) and hematocrit (HCT) (24.3 ′; 4 vs 28.2 ′ 1.5, p <05) than those within the lowest quartile. These data suggest that aluminum toxicity is an important cause of microcytic anemia in outpatient hemodialysis patients. Prospective long-term studies are needed to further define the usefulness of RBC aluminum in diagnosing and following hemodialysis patients with aluminum-induced anemia.",
author = "Brad Yuan and Klein, {Melvyn H.} and Contiguglia, {Robert S.} and Mishell, {Jeffrey L.} and Seligman, {Paul A.} and Miller, {Nancy L.} and Bruce Molitoris and Alfrey, {Allen C.} and Shapiro, {Joseph I.}",
year = "1989",
doi = "10.3109/08860228909066949",
language = "English (US)",
volume = "11",
pages = "91--96",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "2-3",

}

TY - JOUR

T1 - The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population

AU - Yuan, Brad

AU - Klein, Melvyn H.

AU - Contiguglia, Robert S.

AU - Mishell, Jeffrey L.

AU - Seligman, Paul A.

AU - Miller, Nancy L.

AU - Molitoris, Bruce

AU - Alfrey, Allen C.

AU - Shapiro, Joseph I.

PY - 1989

Y1 - 1989

N2 - Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious. Causes of anemia in chronic renal failure are multiple, and at the present time there is no marker for aluminum-induced anemia. Deferoxamine (DFO) treatment can correct aluminum-related anemia and microcytosis, but may be associated with side effects. Because of the possible role of aluminum in red blood cells in causing the anemia associated with aluminum overload, we attempted to test red blood cell (RBC) aluminum as a marker for aluminum-associated anemia and to assess the prevalence of aluminum-associated anemia in an outpatient dialysis population. Both random plasma aluminum and RBC aluminum correlated well with the increase in plasma aluminum seen following DFO challenge. However, RBC aluminum was affected less by changes in oral aluminum intake than plasma aluminum. There were strong correlations of RBC and plasma aluminum to corpuscular volume (MCV) in our patients. Moreover, patients within the highest quartile of RBC aluminum had a lower mean MCV (82.1 ′ 1.7 vs 89.6 ′ 1.7, p <01) and hematocrit (HCT) (24.3 ′; 4 vs 28.2 ′ 1.5, p <05) than those within the lowest quartile. These data suggest that aluminum toxicity is an important cause of microcytic anemia in outpatient hemodialysis patients. Prospective long-term studies are needed to further define the usefulness of RBC aluminum in diagnosing and following hemodialysis patients with aluminum-induced anemia.

AB - Anemia is a well-defined complication of aluminum overload in chronic dialysis patients which may be present before other manifestations of aluminum toxicity are obvious. Causes of anemia in chronic renal failure are multiple, and at the present time there is no marker for aluminum-induced anemia. Deferoxamine (DFO) treatment can correct aluminum-related anemia and microcytosis, but may be associated with side effects. Because of the possible role of aluminum in red blood cells in causing the anemia associated with aluminum overload, we attempted to test red blood cell (RBC) aluminum as a marker for aluminum-associated anemia and to assess the prevalence of aluminum-associated anemia in an outpatient dialysis population. Both random plasma aluminum and RBC aluminum correlated well with the increase in plasma aluminum seen following DFO challenge. However, RBC aluminum was affected less by changes in oral aluminum intake than plasma aluminum. There were strong correlations of RBC and plasma aluminum to corpuscular volume (MCV) in our patients. Moreover, patients within the highest quartile of RBC aluminum had a lower mean MCV (82.1 ′ 1.7 vs 89.6 ′ 1.7, p <01) and hematocrit (HCT) (24.3 ′; 4 vs 28.2 ′ 1.5, p <05) than those within the lowest quartile. These data suggest that aluminum toxicity is an important cause of microcytic anemia in outpatient hemodialysis patients. Prospective long-term studies are needed to further define the usefulness of RBC aluminum in diagnosing and following hemodialysis patients with aluminum-induced anemia.

UR - http://www.scopus.com/inward/record.url?scp=0024817269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024817269&partnerID=8YFLogxK

U2 - 10.3109/08860228909066949

DO - 10.3109/08860228909066949

M3 - Article

C2 - 2623200

AN - SCOPUS:0024817269

VL - 11

SP - 91

EP - 96

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 2-3

ER -